MS 31038

Drug Profile

MS 31038

Latest Information Update: 31 Aug 2007

Price : $50

At a glance

  • Originator Nihon Schering
  • Class Anti-ischaemics
  • Mechanism of Action Sodium hydrogen antiporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Myocardial infarction; Reperfusion injury

Most Recent Events

  • 27 Mar 2000 Mitsui Pharmaceuticals has been acquired by Schering AG
  • 27 Sep 1999 Preclinical development for Reperfusion injury in Japan (Unknown route)
  • 27 Sep 1999 Preclinical development for Myocardial infarction in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top